Idera Pharmaceuticals Inc
IDRA:NASDAQ
| 最新 | 变化/%变化 | 股息收益率 | 交易量 | Avg Volume (10 day) |
| 0.58 | 0.00 0.00% | 0.00% | 0 | 69.3K |
市场数据至少延迟20分钟
Idera Pharmaceuticals Inc的最新新闻标题
Idera Pharmaceuticals Reports 4th Quarter and Full Year 2012 Financial Results
Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2012.
"During the past year, Idera has demonstrated promising clinical activity for the use of Toll-like Receptor antagonists as a novel approach for the potential treatment of autoimmune diseases," said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. "We recently completed dosing in the escalating single-dose portion of our Phase 1 study of IMO-8400, an antagonist of TLRs 7, 8 and 9. In this portion of the trial, IMO-8400 was well-tolerated and showed TLR target engagement at three dose levels in healthy subjects. These results build on the results of our Phase 2 clinical trial of IMO-3100, an antagonist of TLRs 7 and 9, in patients with plaque psoriasis, which we believe provided clinical proof of concept of our approach of targeting specific TLRs for the treatment of psoriasis and other autoimmune and inflammatory diseases."
Idera Pharmaceuticals Reports 4Q and Full Year 2012 Financial Results
Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended Dec. 31, 2012.
"During the past year, Idera has demonstrated promising clinical activity for the use of Toll-like Receptor antagonists as a novel approach for the potential treatment of autoimmune diseases," said Sudhir Agrawal, Chairman and Chief Executive Officer, in a release dated March 11.
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program
查看更多最新标题Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported its financial
and operational results for the fourth quarter and year ended December
31, 2012.
"During the past year, Idera has demonstrated promising clinical
activity for the use of Toll-like Receptor antagonists as a novel
approach for the potential treatment of autoimmune diseases," said
Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. "We
recently completed dosing in the escalating single-dose portion of our
Phase 1 study of IMO-8400, an antagonist of TLRs 7, 8 and 9. In this
portion of the trial, IMO-8400 was well-tolerated and showed TLR target
engagement at three dose levels in healthy subjects. These results build
on the results of our Phase 2 clinical trial of IMO-3100, an antagonist
of TLRs 7 and 9, in patients with plaque psoriasis, which we believe
provided clinical proof of concept of our approach of targeting specific
TLRs for the treatment of psoriasis and other autoimmune and
inflammatory diseases."
公司背景
Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer's disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.
买方价/量 -- / -- | 卖方价/量 -- / -- |
开盘价格 0.00 | 前收盘价格 0.58 |
当天最高 0.00 | 当天最低 0.00 |
52周高/日期 2.19 / 4/17/2012 | 52周低/日期 0.1866 / 3/13/2013 |
% off 52wk High -73.52% | % off 52wk Low 210.83% |
贝他(5年) 1.8 | 市值 16.0M |
流通股数 27.6M | 波动平均(Volatility Avg) 101.92 |
每股收益(EPS)(TTM) -0.93 | 市盈率(P/E) Not Meaningful |
股息宣布日 -- | 股息收益率 0.00% |
除息日 -- | 登记日 -- |
支付数额 0.00 - -- | 支付日期 -- |
上次交易3/18/2013 3:59 PM ET | |
IDRA Idera Pharmaceuticals Inc 对比同行
| 同行 | |
|---|---|
IDRA Idera Pharmaceuticals Inc | -34.83% |
Pfizer Inc. | 11.81% |
Merck & Co., Inc. | 6.57% |
Vertex Pharmaceuticals Incorporated | 22.60% |
Dynavax Technologies Corporation | -25.61% |
IDRA Idera Pharmaceuticals Inc | 0.00% |
Pfizer Inc. | 3.42% |
Merck & Co., Inc. | 3.94% |
Vertex Pharmaceuticals Incorporated | -- |
Dynavax Technologies Corporation | -- |
IDRA Idera Pharmaceuticals Inc | 0.00% |
Pfizer Inc. | 0.00% |
Merck & Co., Inc. | 0.00% |
Vertex Pharmaceuticals Incorporated | 0.00% |
Dynavax Technologies Corporation | 0.00% |